An analysis of the antiemetic protection of metoclopramide plus dexamethasone in Chinese patients receiving moderately high emetogenic chemotherapy

Alexandros Molasiotis, T. S.K. Mok, B. M.C. Yam, H. Yung

Research output: Journal article publicationJournal articleAcademic researchpeer-review

2 Citations (Scopus)

Abstract

This descriptive study aimed to evaluate the antiemetic protection of metoclopramide plus dexamethasone in a sample of 33 Chinese breast cancer patients who were receiving doxorubicin and cyclophosphamide. The antiemetic protection effect was not satisfactory. The results showed that the worst nausea and vomiting was experienced on the third day, with 87.9% of patients reporting nausea and 63.6% experiencing vomiting on that day. In almost one-third of the sample antiemetic medication failed to protect against either acute vomiting or delayed vomiting (i.e. patients continued to experience more than five emetic episodes). Complete protection from acute vomiting was seen in 36.4% of patients, whereas complete protection from delayed vomiting was seen in only one-third of the patients. There was an association between acute nausea/vomiting and delayed nausea/vomiting. Different types of antiemetics need to be offered to Chinese patients receiving chemotherapy (i.e. 5-HT3receptor antagonists or a combination of antiemetics), but more research should be directed to this area.
Original languageEnglish
Pages (from-to)108-113
Number of pages6
JournalEuropean Journal of Cancer Care
Volume11
Issue number2
DOIs
Publication statusPublished - 1 Dec 2002
Externally publishedYes

Keywords

  • Breast cancer
  • Chinese
  • Cyclophosphamide
  • Doxorubicin
  • Metoclopramide
  • Nausea
  • Vomiting

ASJC Scopus subject areas

  • Oncology

Cite this